ACT-128800

DRUG5 trials

Sponsors

Actelion

Conditions

HealthyPharmacokineticsPlaque PsoriasisPsoriasisSafety and Tolerability

Phase 1

Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-128800 in Healthy Subjects

CompletedNCT02029482

ActelionSafety and Tolerability

Start: 2010-04-30End: 2010-06-30Updated: 2014-01-08

Mass Balance, Pharmacokinetics, and Metabolism of 14C-labeled ACT-128800 Administered to Healthy Male Subjects

CompletedNCT02126956

ActelionPharmacokinetics

Start: 2009-03-31End: 2009-04-30Updated: 2014-04-30

Study to Evaluate the Pharmacokinetics, Tolerability, and Safety of ACT-128800 in Japanese and Caucasian Healthy Male and Female Subjects

CompletedNCT02223832

ActelionHealthy

Start: 2009-02-28End: 2009-04-30Updated: 2014-08-22

Phase 2

ACT-128800 in Psoriasis

CompletedNCT00852670

ActelionPlaque Psoriasis

Start: 2008-10-31End: 2009-09-30Updated: 2009-11-13

ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis

CompletedNCT01208090

ActelionPsoriasis

Start: 2010-10-31End: 2012-11-30Updated: 2025-03-30

Related Papers

Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial.

2014-08-10119 citations